1.64 USD
-0.04 (-2.38%)
Taking everything into account, TXMD scores 4 out of 10 in our fundamental rating. TXMD was compared to 192 industry peers in the Pharmaceuticals industry. While TXMD seems to be doing ok healthwise, there are quite some concerns on its profitability. TXMD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
TXMD had positive earnings in the past year.
In the past year TXMD had a positive cash flow from operations.
TXMD had negative earnings in 4 of the past 5 years.
In the past 5 years TXMD reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.78%, TXMD is in the better half of the industry, outperforming 79.17% of the companies in the same industry.
With an excellent Return On Equity value of 1.10%, TXMD belongs to the best of the industry, outperforming 81.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.78% | ||
| ROE | 1.1% | ||
| ROIC | N/A |
ROA(3y)31.47%
ROA(5y)-21.67%
ROE(3y)92.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TXMD's Profit Margin of 10.80% is amongst the best of the industry. TXMD outperforms 84.38% of its industry peers.
TXMD does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 10.8% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TXMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TXMD has about the same amount of shares outstanding.
The number of shares outstanding for TXMD has been increased compared to 5 years ago.
There is no outstanding debt for TXMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -33.27, we must say that TXMD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -33.27, TXMD is doing worse than 89.58% of the companies in the same industry.
TXMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | -33.27 |
ROIC/WACCN/A
WACC9.4%
2.3 Liquidity
TXMD has a Current Ratio of 2.93. This indicates that TXMD is financially healthy and has no problem in meeting its short term obligations.
TXMD's Current ratio of 2.93 is in line compared to the rest of the industry. TXMD outperforms 52.08% of its industry peers.
A Quick Ratio of 2.93 indicates that TXMD has no problem at all paying its short term obligations.
With a Quick ratio value of 2.93, TXMD perfoms like the industry average, outperforming 55.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.93 | ||
| Quick Ratio | 2.93 |
3. Growth
3.1 Past
TXMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 102.21%, which is quite impressive.
The Revenue has grown by 75.19% in the past year. This is a very strong growth!
The Revenue for TXMD have been decreasing by -48.72% on average. This is quite bad
EPS 1Y (TTM)102.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.74%
Revenue 1Y (TTM)75.19%
Revenue growth 3Y-11.84%
Revenue growth 5Y-48.72%
Sales Q2Q%43.33%
3.2 Future
Based on estimates for the next years, TXMD will show a decrease in Earnings Per Share. The EPS will decrease by -8.87% on average per year.
Based on estimates for the next years, TXMD will show a small growth in Revenue. The Revenue will grow by 1.92% on average per year.
EPS Next Y0%
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
EPS Next 5Y-8.87%
Revenue Next Year1.11%
Revenue Next 2Y1.65%
Revenue Next 3Y1.82%
Revenue Next 5Y1.92%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 164.00, TXMD can be considered very expensive at the moment.
TXMD's Price/Earnings ratio is a bit cheaper when compared to the industry. TXMD is cheaper than 76.56% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.61, TXMD is valued quite expensively.
TXMD is valuated reasonably with a Price/Forward Earnings ratio of 9.46.
TXMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. TXMD is cheaper than 87.50% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of TXMD to the average of the S&P500 Index (24.01), we can say TXMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 164 | ||
| Fwd PE | 9.46 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, TXMD is valued cheaply inside the industry as 91.67% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.18 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TXMD's earnings are expected to decrease with -18.42% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
5. Dividend
5.1 Amount
TXMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:TXMD (12/23/2025, 3:57:57 PM)
1.64
-0.04 (-2.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners28.6%
Inst Owner Change1.48%
Ins Owners1.55%
Ins Owner Change0%
Market Cap18.97M
Revenue(TTM)2.80M
Net Income(TTM)302.00K
Analysts43.33
Price TargetN/A
Short Float %0.49%
Short Ratio0.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 164 | ||
| Fwd PE | 9.46 | ||
| P/S | 6.79 | ||
| P/FCF | 9.18 | ||
| P/OCF | 9.18 | ||
| P/B | 0.69 | ||
| P/tB | 0.81 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.01
EY0.61%
EPS(NY)0.17
Fwd EY10.57%
FCF(TTM)0.18
FCFY10.9%
OCF(TTM)0.18
OCFY10.9%
SpS0.24
BVpS2.37
TBVpS2.03
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.78% | ||
| ROE | 1.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 10.8% | ||
| GM | N/A | ||
| FCFM | 73.96% |
ROA(3y)31.47%
ROA(5y)-21.67%
ROE(3y)92.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 684.77% | ||
| Current Ratio | 2.93 | ||
| Quick Ratio | 2.93 | ||
| Altman-Z | -33.27 |
F-Score8
WACC9.4%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.74%
EPS Next Y0%
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
EPS Next 5Y-8.87%
Revenue 1Y (TTM)75.19%
Revenue growth 3Y-11.84%
Revenue growth 5Y-48.72%
Sales Q2Q%43.33%
Revenue Next Year1.11%
Revenue Next 2Y1.65%
Revenue Next 3Y1.82%
Revenue Next 5Y1.92%
EBIT growth 1Y45.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y101.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y101.47%
OCF growth 3YN/A
OCF growth 5YN/A
THERAPEUTICSMD INC / TXMD FAQ
What is the ChartMill fundamental rating of THERAPEUTICSMD INC (TXMD) stock?
ChartMill assigns a fundamental rating of 4 / 10 to TXMD.
What is the valuation status for TXMD stock?
ChartMill assigns a valuation rating of 4 / 10 to THERAPEUTICSMD INC (TXMD). This can be considered as Fairly Valued.
What is the profitability of TXMD stock?
THERAPEUTICSMD INC (TXMD) has a profitability rating of 3 / 10.
What is the valuation of THERAPEUTICSMD INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for THERAPEUTICSMD INC (TXMD) is 164 and the Price/Book (PB) ratio is 0.69.
What is the expected EPS growth for THERAPEUTICSMD INC (TXMD) stock?
The Earnings per Share (EPS) of THERAPEUTICSMD INC (TXMD) is expected to decline by 0% in the next year.